Replies to post #31163 on Revive Therapeutics Ltd (RVVTF)

[Ecomike]

Thank you, much appreciated. Comforting to know I am not the only here with my head screwed on straight.

This is also an awesome run down you posted:

"Hey Ecomike you have just composed one of the best posts I have read on any board concerning Revive! Well done sir!! I have also been trading in the Biotech space in time measured in decades. The most shocking thing to me is that there are so many “investors” that are shocked! The fact is this is a “micro” cap company; they have extremely limited resources, are playing with the big boys and frankly have done very well overall."

YES!!! "The FDA obviously likes this drug or they would not have pushed us into a phase 3. They are nearly at the 800 mile stone and once the dosing starts in Turkey the last 85 will go quickly.

No one likes to see their investment down 60% or deal with missed deadlines etc.. Hell we all would have liked to see them finish the trial in Q3 of last year and be retired especially MF and the board at Revive!!

The science and safety profile of this drug are extremely strong, there is still a big need and the trial will get finished. Covid isn’t going anywhere and we are still well positioned to take advantage of the world wide scramble that looks to be on the horizon again this fall.

Those that have lost their patience and are selling at a loss at these prices will most certainly IMHO regret it. Hopefully they will learn a powerful lesson that they can lean on and keep themselves from throwing money away in the future!! I am not selling a share and at these prices will be adding to the pile! GLTA! "

[Ecomike]

This weeks old news alone is a massive clue, Massive!!!

"Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation • InvestorsHub NewsWire • 02/16/2022 01:03:51 PM"

That does not happen for something the FDA is going deny an EUA approval for....

IMO, there is a connection there. And that designation is worth about 3 Million dollars of cost savings, and gives $RVVTF rights to it, on safely used for 30 years drug, used for RA....